35
Participants
Start Date
January 1, 2020
Primary Completion Date
April 1, 2026
Study Completion Date
June 1, 2028
LIPOSORBER® LA-15
"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."
RECRUITING
Weill Cornell Medicine / NewYork-Presbyterian, New York
RECRUITING
Nemours/Alfred I DuPont Hospital for Children, Wilmington
RECRUITING
Children's Hospital of Richmond at VCU, Richmond
RECRUITING
University of North Carolina, Chapel Hill
RECRUITING
Medical University of South Carolina Children's Hospital, Charleston
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Akron Children's Hospital, Akron
RECRUITING
Helen DeVos Children's Hospital, Grand Rapids
RECRUITING
Loma Linda University Children's Hospital, Loma Linda
RECRUITING
Loma Linda University Hospital, Loma Linda
Kaneka Medical America LLC
INDUSTRY